Aptamer Group publishes new Corporate Presentation and Investor Factsheet

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next generation synthetic binders delivering innovation to the life science industry, has announced that it has published a new corporate presentation and investor factsheet.

The corporate presentation outlines Aptamer’s strategy, operational progress and financial performance, offering a comprehensive overview of the Group’s growth potential. Complementing this, the investor factsheet provides a succinct two-page summary, focused on highlighting key operational and financial metrics to support investors in their evaluation of the Group.

No new material information has been disclosed in either of these publications.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Aptamer Group retail offer raises £274,000, total fundraise reaches £4.5 million

Aptamer Group said its retail offer closed having raised about £274,000 before expenses. Subject to shareholder approval at the general meeting on 13 April 2026, the company expects to issue 45.7 million shares at 0.6p each, bringing total gross proceeds from the placing, subscription and retail offer to about £4.5 million.

Aptamer Group launches retail offer to raise up to £0.5 million at 0.6p per share

Aptamer Group plc has opened a UK retail offer through the BookBuild Platform to raise up to £0.5 million by issuing up to 83.3 million new ordinary shares at 0.6 pence each, with one warrant for every three shares subscribed.

Aptamer Group reports higher H1 revenue and launches £3.75m bookbuild

Aptamer Group said H1 2026 revenue rose 27% to £0.83 million, with progress across licensing, fee-for-service contracts and asset development. The company also announced a bookbuild expected to raise at least £3.75 million to extend cash runway into 2028.

Aptamer expands pipeline with targeted radiopharmaceutical initiative

Aptamer Group is developing a proprietary radiopharmaceutical pipeline using its Optimer® platform, supported by a partnership with Radiopharmium Ltd and early data indicating improved radioligand stability compared to existing approaches.

Aptamer and Metir advance real-time water pathogen detection programme

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer® binders into a continuous waterborne pathogen detection system.

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer® binders to enable room-temperature stability in next-generation sequencing workflows.

    Search